Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Norucholic Acid in Primary Sclerosing Cholangitis (NUT-022/PSC)
NCT06886360Phase 3Not yet recruiting
- Sponsor
- Dr. Falk Pharma GmbH
- Start
- Mar 2025
- Primary completion
- Sep 2027
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of norursodeoxycholic acid in Primary Sclerosing Cholangitis (PSC), sponsored by Dr. Falk Pharma GmbH. Primary endpoints: Occurrence of treatment emergent adverse events at 72 weeks, Occurrence of serious treatment emergent adverse events at 72 weeks and 5 more. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
norursodeoxycholic acid
03
Conditions
Primary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on NCT06886360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06886360.